Trans surgeries increase risk of mental health conditions, suicidal ideations: study
So-called "gender-affirming surgery" could lead to dangerous mental health effects, a new study has found.
Transgender individuals face "heightened psychological distress," including depression, anxiety and suicidal ideation, "partly due to stigma and lack of gender affirmation," as stated in the study, which was published in The Journal of Sexual Medicine.
Researchers from the University of Texas set out to determine the mental health impacts from transgender people who underwent "gender-affirming surgery."
The study focused on 107,583 patients 18 and over with gender dysphoria, some who underwent surgery and others who did not.
They determined rates of depression, anxiety, suicidal ideation and substance-use disorders were "significantly higher" among those who underwent surgery, assessed two years later.
Males with surgery had depression rates of 25% compared to males without surgery (11.5%). Anxiety rates among that group were 12.8% compared to 2.6%.
Depression, anxiety, suicidal ideation and substance-use disorders were "significantly higher" among those who underwent surgery.
The same differences were seen among females, as those with surgery had 22.9% depression rates compared to 14.% in the non-surgical group.
Females who had surgery also had anxiety rates of 10.5% compared to 7.1% without surgery.
Surgeries that aimed to "feminize individuals" showed "particularly high" rates of depression and substance abuse two years after the procedures, the study found.
"Findings suggest the necessity for gender-sensitive mental health support following gender-affirming surgery to address post-surgical psychological risks," the researchers wrote.
Jonathan Alpert, a Manhattan-based psychotherapist and author, said the study findings highlight the "often overlooked" psychological risks that accompany gender-affirming surgery.
"While these surgeries can be critical in helping individuals align their physical appearance with their gender identity, they are not a cure-all for the mental health challenges many transgender individuals face," Alpert told Fox News Digital.
"These findings suggest that surgery alone doesn't eliminate the complex psychological burdens that stem from societal stigma and personal struggles with identity," he went on.
"In fact, taking a scalpel to treat a psychological disorder can sometimes lead to more issues as the study results are elucidating."
Florida neurosurgeon Dr. Brett Osborn agreed that "surgery is no guarantee of happiness."
"The key question remains: Is the surgery itself causing distress, or are preexisting mental health issues driving people toward it? Correlation or causation? No one knows."
A 2022 study showed that around 1.4 million American adults identify as transgender and about 0.6% of all American adults experience gender dysphoria.
"The dramatic upward trend of gender dysphoria among young people in recent years should raise serious questions about the role of cultural and social influences," Alpert said.
"While increased awareness has made it easier for some children to express their struggles, we cannot ignore the possibility that social contagion, along with peer influence and social media — may be contributing to this surge."
Teens who are being treated for gender dysphoria should be "properly supported and treated with compassion" without being pressured into making "life-altering" medical decisions, Alpert advised.
"Gender-affirming surgery is aggressive, permanent and laden with risk."
Both experts caution against rushing into surgery or other irreversible decisions.
"Remember, gender-affirming surgery is aggressive, permanent and laden with risk," Osborn told Fox News Digital.
He expressed the same cautions about hormone therapy — "we're talking about irreversible changes that demand lifelong management."
For more Health articles, visit www.foxnews.com/health
"Too many rush into these interventions without fully understanding the consequences," he went on. "The push for faster access to these procedures ignores a critical reality: Long-term psychiatric support is essential."
Fox News Digital reached out to the study researchers requesting comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ReproTech LLC ("ReproTech") has made a significant growth investment in Matcher Technologies Ltd ("Matcher") to support its expansion across the fertility sector
DOVER, Del., June 9, 2025 /PRNewswire/ -- ReproTech, a leading provider of reproductive cryostorage and cryostorage technology solutions, is pleased to announce a significant investment in Matcher Technologies Ltd, a recognized innovator in the fertility industry known for its flagship electronic witnessing product, IMT Matcher. This strategic investment strengthens ReproTech's leadership in cryostorage by enhancing its existing traceability solutions. The integration of Matcher's expertise and technology with ReproTech's existing suite of cryostorage and safety focused products marks a major step towards the first comprehensive platform for patients and clinics to digitally document every step of the IVF process while providing the safest storage solutions on the market. "We are thrilled to partner with Matcher to continue our combined journey of providing the highest quality, safest and most compliant products for our clinic partners," said Brad Senstra, ReproTech CEO. "Their team, technology, mission and values align perfectly with our commitment to exceptional service, advanced technologies, and stringent compliance standards." Matcher Technologies Ltd, founded in 2005, has built a strong reputation for the capability and quality of its product, continual innovation, and excellent customer service. Following the investment, Matcher's operations will continue from its U.K. headquarters uninterrupted for end users and the existing distributor network. "ReproTech's reputation as a trusted storage solutions partner—with 35 years of experience—and their dedication to advancing traceability in fertility care make them an ideal partner," said George Heywood, CEO of Matcher Technologies Ltd. "Together, we can drive innovation and enhance our service offerings in both domestic and international markets." ReproTech was advised by Shoosmiths LLP, BDO LLP, and Armstrong Teasdale LLP. Matcher Technologies Ltd was supported by Clearwater International, Brabners LLP, and Claritas Tax. For more information, visit the Reprotech or IMT Matcher website or contact: Media Contact:Joy ZardeckiSVP Business Development & Administrationjzardecki@ About ReproTech ReproTech is a Delaware-based provider of cryostorage technology solutions, off-site storage and logistics services. The company partners with fertility clinics, hospital systems, donor banks, and andrology laboratories across North America to offer secure, state-of-the-art storage for sperm, oocytes, embryos, stem cells, oncofertility specific tissues, and other reproductive tissues - ensuring patients have future options for family formation. ReproTech distinguishes itself through exceptional service, advanced technologies, and stringent compliance standards. Learn more at About Matcher Technologies Ltd Matcher Technologies Ltd. is a UK based, global leader in fertility technology, renowned for developing IMT Matcher - the world's first electronic witnessing system - over 20 years ago. Over the past two decades, the company has played a pivotal role in shaping industry standards and educating the market. Built on insights from hundreds of fertility center customers worldwide, IMT Matcher has become the highest quality witnessing and traceability system of choice for clinics across the globe. With a deep commitment to innovation, Matcher has continuously invested in product development, driven by a highly skilled, multi-disciplinary, global team. The company's commitment to quality is underscored by longstanding relationships with global players and a trusted reputation for delivering excellent customer service in pursuit of protecting patients, fertility centers and donor banks from the risks of error in IVF. Learn more at View original content to download multimedia: SOURCE ReproTech, LLC Sign in to access your portfolio
Atlantic
2 hours ago
- Atlantic
‘We're Just Becoming a Weapon of the State'
Since winning President Donald Trump's nomination to serve as the director of the National Institutes of Health, Jay Bhattacharya—a health economist and prominent COVID contrarian who advocated for reopening society in the early months of the pandemic—has pledged himself to a culture of dissent. 'Dissent is the very essence of science,' Bhattacharya said at his confirmation hearing in March. 'I'll foster a culture where NIH leadership will actively encourage different perspectives and create an environment where scientists, including early-career scientists and scientists that disagree with me, can express disagreement, respectfully.' Two months into his tenure at the agency, hundreds of NIH officials are taking Bhattacharya at his word. More than 300 officials, from across all of the NIH's 27 institutes and centers, have signed and sent a letter to Bhattacharya that condemns the changes that have thrown the agency into chaos in recent months—and calls on their director to reverse some of the most damaging shifts. Since January, the agency has been forced by Trump officials to fire thousands of its workers and rescind or withhold funding from thousands of research projects. Tomorrow, Bhattacharya is set to appear before a Senate appropriations subcommittee to discuss a proposed $18 billion slash to the NIH budget—about 40 percent of the agency's current allocation. The letter, titled the Bethesda Declaration (a reference to the NIH's location in Bethesda, Maryland), is modeled after the Great Barrington Declaration, an open letter published by Bhattacharya and two of his colleagues in October 2020 that criticized 'the prevailing COVID-19 policies' and argued that it was safe—even beneficial—for most people to resume life as normal. The approach that the Great Barrington Declaration laid out was, at the time, widely denounced by public-health experts, including the World Health Organization and then–NIH director Francis Collins, as dangerous and scientifically unsound. The allusion in the NIH letter, officials told me, isn't meant glibly: 'We hoped he might see himself in us as we were putting those concerns forward,' Jenna Norton, a program director at the National Institute of Diabetes and Digestive and Kidney Diseases, and one of the letter's organizers, told me. None of the NIH officials I spoke with for this story could recall another time in their agency's history when staff have spoken out so publicly against a director. But none of them could recall, either, ever seeing the NIH so aggressively jolted away from its core mission. 'It was time enough for us to speak out,' Sarah Kobrin, a branch chief at the National Cancer Institute, who has signed her name to the letter, told me. To preserve American research, government scientists—typically focused on scrutinizing and funding the projects most likely to advance the public's health—are now instead trying to persuade their agency's director to help them win a political fight with the White House. Bhattacharya, the NIH, and the Department of Health and Human Services did not respond immediately to a request for comment. The agency spends most of its nearly $48 billion budget powering science: It is the world's single-largest public funder of biomedical research. But since January, the NIH has canceled thousands of grants —originally awarded on the basis of merit—for political reasons: supporting DEI programming, having ties to universities that the administration has accused of anti-Semitism, sending resources to research initiatives in other countries, advancing scientific fields that Trump officials have deemed wasteful. Prior to 2025, grant cancellations were virtually unheard-of. But one official at the agency, who asked to remain anonymous out of fear of professional repercussions, told me that staff there now spend nearly as much time terminating grants as awarding them. And the few prominent projects that the agency has since been directed to fund appear either to be geared toward confirming the administration's biases on specific health conditions, or to benefit NIH leaders. 'We're just becoming a weapon of the state,' another official, who signed their name anonymously to the letter, told me. 'They're using grants as a lever to punish institutions and academia, and to censor and stifle science.' NIH officials have tried to voice their concerns in other ways. At internal meetings, leaders of the agency's institutes and centers have questioned major grant-making policy shifts. Some prominent officials have resigned. Current and former NIH staffers have been holding weekly vigils in Bethesda, commemorating, in the words of the organizers, ' the lives and knowledge lost through NIH cuts.' (Attendees are encouraged to wear black.) But these efforts have done little to slow the torrent of changes at the agency. Ian Morgan, a postdoctoral fellow at the NIH and one of the letter's signers, told me that the NIH fellows union, which he is part of, has sent Bhattacharya repeated requests to engage in discussion since his first week at the NIH. 'All of those have been ignored,' Morgan said. By formalizing their objections and signing their names to them, officials told me, they hope that Bhattacharya will finally feel compelled to respond. (To add to the public pressure, Jeremy Berg, who led the NIH's National Institute of General Medical Sciences until 2011, is also organizing a public letter of support for the Bethesda Declaration, in partnership with Stand Up for Science, which has organized rallies in support of research.) Scientists elsewhere at HHS, which oversees the NIH, have become unusually public in defying political leadership, too. Last month, after Health Secretary Robert F. Kennedy Jr.—in a bizarre departure from precedent—announced on social media that he was sidestepping his own agency, the CDC, and purging COVID shots from the childhood-immunization schedule, CDC officials chose to retain the vaccines in their recommendations, under the condition of shared decision making with a health-care provider. Many signers of the Bethesda letter are hopeful that Bhattacharya, 'as a scientist, has some of the same values as us,' Benjamin Feldman, a staff scientist at the National Institute of Child Health and Human Development, told me. Perhaps, with his academic credentials and commitment to evidence, he'll be willing to aid in the pushback against the administration's overall attacks on science, and defend the agency's ability to power research. But other officials I spoke with weren't so optimistic. Many at the NIH now feel they work in a 'culture of fear,' Norton said. Since January, NIH officials have told me that they have been screamed at and bullied by HHS personnel pushing for policy changes; some of the NIH leaders who have been most outspoken against leadership have also been forcibly reassigned to irrelevant positions. At one point, Norton said, after she fought for a program focused on researcher diversity, some members of NIH leadership came to her office and cautioned her that they didn't want to see her on the next list of mass firings. (In conversations with me, all of the named officials I spoke with emphasized that they were speaking in their personal capacity, and not for the NIH.) Bhattacharya, who took over only two months ago, hasn't been the Trump appointee driving most of the decisions affecting the NIH—and therefore might not have the power to reverse or overrule them. HHS officials have pressured agency leadership to defy court orders, as I've reported; mass cullings of grants have been overseen by DOGE. And as much as Bhattacharya might welcome dissent, he so far seems unmoved by it. In early May, Berg emailed Bhattacharya to express alarm over the NIH's severe slowdown in grant making, and to remind him of his responsibilities as director to responsibly shepherd the funds Congress had appropriated to the agency. The next morning, according to the exchange shared with me by Berg, Bhattacharya replied saying that, 'contrary to the assertion you make in the letter,' his job was to ensure that the NIH's money would be spent on projects that advance American health, rather than 'on ideological boondoggles and on dangerous research.' And at a recent NIH town hall, Bhattacharya dismissed one staffer's concerns that the Trump administration was purging the identifying variable of gender from scientific research. (Years of evidence back its use.) He echoed, instead, the Trump talking point that 'sex is a very cleanly defined variable,' and argued that gender shouldn't be included as 'a routine question in order to make an ideological point.' The officials I spoke with had few clear plans for what to do if their letter goes unheeded by leadership. Inside the agency, most see few levers left to pull. At the town hall, Bhattacharya also endorsed the highly contentious notion that human research started the pandemic—and noted that NIH-funded science, specifically, might have been to blame. When dozens of staffers stood and left the auditorium in protest, prompting applause that interrupted Bhattacharya, he simply smiled
Business Wire
2 hours ago
- Business Wire
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at
